Specialty drugmaker and IBD 50 stock Jazz Pharmaceuticals reported Q2 earnings in line with estimates and affirmed its guidance late Wednesday, but its revenue came up a bit short of expectations. Jazz (JAZZ) said that its earnings rose 19% over the year-earlier quarter to $2.41 a share, while revenue increased 15% to $333.7 million. Analysts expected $335.9 million in revenue. The EPS number matched their estimate, according to Thomson Reuters.
SoftBank CEO Masayoshi Son took center stage on Sprint’s earnings conference call with analysts Tuesday, declaring he will not sell the struggling wireless firm and disclosing new off-balance-sheet financing plans aimed at keeping Sprint’s turnaround on track. Sprint (S)stock rose 4.5% Tuesday to 3.49 after the wireless carrier reported better-than-expected subscriber metrics in the June quarter, raised its 2015 EBITDA guidance and named a new
LinkedIn reported better-than-expected Q2 earnings after the market close Thursday, but the stock reversed downward after an initial spike in after-hours trading. LinkedIn (LNKD) reported Q2 revenue of $711.7 million, beating the consensus estimate of $680 million and up 33% from the year-earlier quarter. Earnings per share minus items rose 8% to 55 cents, the slowest growth in four quarters but beating the 30-cent estimate of analysts polled by Thomson